Brian I. Rini, M.D.

Vanderbilt-Ingram Cancer Center
Chief of Clinical Trials
Ingram Professor of Cancer Research

Vanderbilt University Medical Center

Professor of Medicine, Hematology Oncology
Brian Rini, MD | Kidney Cancer Research Consortium
Dr. Brian I. Rini, MD, FASCO, stands as a prominent figure in kidney cancer clinical research, holding the esteemed positions of Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Professor of Medicine at Vanderbilt University. With a prolific career marked by extensive publications, leadership roles in prominent organizations, and impactful contributions to clinical trials, Dr. Rini is a driving force in advancing genitourinary cancer research.


Education & Training

The Ohio State University College of Medicine
Psychology, University of Notre Dame, South Bend, Indiana


Professional Appointments and Leadership:

As the Chief of Clinical Trials at VICC, Dr. Rini spearheads kidney cancer clinical research, emphasizing the expansion of cancer clinical research operations. His role as the Ingram Professor of Medicine at Vanderbilt University reflects his leadership in academia, where he not only conducts groundbreaking research but also imparts knowledge to future generations of medical professionals.


Research and Publications:

Dr. Rini’s research activities are a testament to his dedication to advancing knowledge in genitourinary cancer, particularly renal cell carcinoma. With over 300 publications to his name, he has significantly contributed to the scientific discourse surrounding kidney cancer. Notably, he has served as the lead investigator for several phase 3 clinical trials, playing a pivotal role in obtaining FDA approvals for novel treatments.

Clinical Expertise and Recognition:

Dr. Rini’s leadership roles in prominent organizations, including ASCO, Kidney Cancer Association (KCA), and the Society for Immunotherapy of Cancer (SITC), highlight his commitment to shaping the landscape of cancer care and research. Additionally, his former service as Chair of the Oncologic Drugs Advisory Committee (ODAC) reflects his influence in guiding drug development and approvals.


Leadership & Impact:

As a member of SITC and through his extensive involvement in clinical trials, Dr. Rini showcases a commitment to advancing immunotherapy approaches in cancer treatment. His contributions in this realm contribute to the ongoing evolution of cancer therapies.

Additionally, Dr. Rini is the Dean of the Academy of Kidney Cancer Investigators, which fosters the development and commitment of early career kidney cancer researchers, and a founder of the Uromigos podcast, which strives to provide balanced, scientific content related to care of patients with GU malignancies

In summary, Dr. Brian Rini’s distinguished career is characterized by a profound commitment to kidney cancer clinical research, leadership in academia, and significant contributions to the field of genitourinary cancer. His multifaceted role as a researcher, educator, and advocate underscores his enduring impact on cancer care and positions him as a key figure in advancing the understanding and treatment of renal cell carcinoma.

“There are still a lot of unmet needs in RCC treatment. I’m hopeful that over the next 2, 3, or 5 years, we’ll be doing patient-specific therapy and less empirical therapy.”


Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Naomi Haas, MD | Kidney Cancer Research Consortium

Naomi Haas


Daniel George, MD | Kidney Cancer Research Consortium

Daniel George

Duke University

Hans Hammers

UT Southwestern
Eric Jonasch, M.D. | Kidney Cancer Research Consortium

Eric Jonasch

MD Anderson

David McDermott, MD | Kidney Cancer Research Consortium

David McDermott

Beth Israel

Ulka Vaishampayan, MD | Kidney Cancer Research Consortium

Ulka Vaishampayan

University of Michigan